Drug Profile
Frovocimab - Eli Lilly and Company
Alternative Names: LY3015014Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperlipidaemics; Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypercholesterolaemia
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Hypercholesterolaemia in USA (IV, Infusion)
- 07 Apr 2016 Phase-II development of SC formulation is ongoing
- 01 Jun 2014 Eli Lilly completes a phase II trial in Hypercholesterolaemia in the US, Canada, Czech Republic, Denmark, Japan, Netherlands, Poland and Puerto Rico (NCT01890967)